The compound state: Hb S/beta-thalassemia  by Figueiredo, Maria Stella
rev bras hematol hemoter. 2 0 1 5;3  7(3):150–152
www.rbhh.org
Revista Brasileira de Hematologia e Hemoterapia
Brazilian Journal of Hematology and Hemotherapy
Scientiﬁc Comment
The  compound  state:  Hb  S/beta-thalassemiaMaria Stella Figueiredo ∗
16Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
Sickle cell disease (SCD) results from a single amino acid
substitution in the gene encoding the -globin subunit
(6Glu > Val) that produces the abnormal hemoglobin (Hb)
named Hb S. SCD has different genotypes with substantial
variations in presentation and clinical course (Table 1).1,2 The
combination of the sickle cell mutation and beta-thalassemia
(-Thal) mutation gives rise to a compound heterozygous con-
dition known as Hb S/  thalassemia (Hb S/-Thal), which was
ﬁrst described in 1944 by Silvestroni and Bianco.3
The polymerization of deoxygenated Hb S (sickling) is the
primary event in the molecular pathogenesis of SCD. How-
ever, this event is highly dependent on the intracellular Hb
composition; in other words, it is dependent on the concen-
tration of Hb S, and type and concentration of the other types
of Hb. Therefore, the major primary genetic determinant of
the severity of SCD is the genotype.2,4–6
Many  different -Thal mutations have been associated
with Hb S, and the molecular basis of the thalassemia in Hb
S/-Thal individuals reﬂects the spectrum of -Thal mutations
observed in a particular population.5,7–12 The heterogeneity of
the -Thal mutations leads to quantitatively different -globin
synthesis and consequently to different amounts of Hb A. This
fact results in variable clinical manifestations, ranging from
nearly asymptomatic to a severe condition similar to sickle cell
anemia (homozygous Hb S).3,13 There is no consensus about
the classiﬁcation of Hb S/-Thal, but it is usually classiﬁed in
two types: Hb S/0-Thal and Hb S/+-Thal.2,4
Hb S/0-Thal, in which the production of Hb A is abol-
ished, is often clinically indistinguishable from sickle cell
anemia. The thalassemia acts on sickled red blood cells,
inducing microcytosis, hypochromia, and sometimes Hb F
is elevated. This result in an improvement of the circulatory
competence of these cells, a reduction of hemolysis, and a
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reserved.small increase in Hb concentration and in packed cell volume.
However, these effects are not accompanied by any reduction
in vaso-occlusive events, probably due to the great number of
Hb S-containing red blood cells resulting in increased blood
viscosity.4,5
A confusing diagnostic problem is the differentiation
of Hb S/0-Thal from sickle cell anemia associated with
-thalassemia. Table 2 shows that hematologic and elec-
trophoretic studies are unable to distinguish between the two
conditions and so family studies and DNA analysis are needed
to conﬁrm the diagnosis.5
In Hb S/+-Thal, variable amounts of Hb A dilute Hb S and
consequently inhibit polymerization-induced cellular dam-
age. The Hb A levels vary from <5% to 45% of the hemolysate
and higher levels of Hb A are usually associated with a
milder phenotype.5,8,12–15 However, because of the confound-
ing inﬂuences of other genetic modiﬁers, such as -globin gene
expression and -thalassemia, a rigid genotype–phenotype
correlation is difﬁcult to establish.5
A classiﬁcation of Hb S/+-Thal into Types I (Hb A: 1–7%),
II (Hb A: 7–14%), or III (Hb A: 14–25%) according to the level of
Hb A has been proposed.3,14 However, this classiﬁcation is not
widely accepted and could be considered of little utility. Nowa-
days it is possible to deﬁne the -Thal mutation exactly by
molecular biology techniques, and determine the relationship
between mutation and clinical manifestations.5
The determination of the -Thal mutation in Hb S/+-Thal
individuals was performed by Besilario et al. These authors
studied four patients with an Hb A concentration above 38%
and a very mild form of the disease, and identiﬁed two muta-037-002, Vila Clementino, São Paulo, SP, Brazil.
tions for the ﬁrst time in the Brazilian population. It is
important to point out that these cases could be wrongly inter-
preted as sickle cell trait, since they had no anemia, despite
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Table 1 – Sickle cell disease genotypes.
Severe sickle cell disease
Sickle cell anemia (Hb S/S) 6Glu > Val/6Glu > Val The most common form
Hb S/0 thalassemia Multiple mutations Most prevalent in the eastern
Mediterranean region and India
Severe Hb S/+ thalassemia Multiple mutations Most prevalent in the eastern
Mediterranean region and India
Hb S/O Arab 6Glu > Val/121Glu > Lys North Africa, the Middle East, and the
Balkans
Hb S/D Punjab 6Glu  > Val/121Glu > Gln Predominant in northern India
Hb S/C Harlem 6Glu  > Val/6Glu > Val/,  73Asp > Asn Very rare
Moderate sickle cell disease
Hb S/C 6Glu > Val/6Glu > Lys 25–30% cases of sickle cell disease of
African origin
Moderate Hb S/+ thalassemia Multiple mutations Most in the eastern Mediterranean region
Mild sickle cell disease
Mild Hb S/++ thalassemia Multiple mutations Mostly in populations of African origin
Hb S/E 6Glu > Val/26Glu > Lys Hb E predominates in southeast Asia
Very mild sickle cell disease
Hb S/Hereditary Persistence of Fetal Hemoglobin Large deletions of the -globin gene complex
Source: Modiﬁed from Rees et al.1
Table 2 – Laboratory differentiation of sickle cell anemia, sickle cell anemia/-thalassemia, and Hb S/0-thalassemia.
Diagnosis Level variation Mean Hb F (%)
Hemoglobin (g/dL) MCV (ﬂ) Hb A2 (%)
SCA 7–8 85–95 2.5–3.5 5
SCA/-thalassemia 8–10 70–85 3.5–4.5 5
Hb S/0-thalassemia 8–10 65–75 4–6 9
Source: Modiﬁed from Steinberg et al.5
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1SCA: sickle cell anemia; MCV: mean corpuscular volume; Hb A2: hem
 little microcytosis, and that this incorrect diagnosis would
eﬂect in the genetic counseling provided. In summary, this
tudy reinforces the importance of molecular studies in our
opulation, in order to enhance our knowledge about the dis-
ase in Brazil and consequently improve genetic counseling,
ollow up, and treatment.
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